NASDAQ:CCXIChemoCentryx Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ChemoCentryx Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $55.24 +0.75 (+1.38 %) (As of 08/7/2020 04:00 PM ET) Add Compare Share Today's Range$54.18Now: $55.24▼$56.5450-Day Range$52.20MA: $56.28▼$61.6952-Week Range$6.37Now: $55.24▼$65.43Volume377,049 shsAverage Volume557,684 shsMarket Capitalization$3.42 billionP/E RatioN/ADividend YieldN/ABeta1.94 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis; CCX507, a second generation CCR9 inhibitor, which has completed Phase I clinical trial; and CCX872, a potent and selective inhibitor of CCR2, which is in phase Ib clinical trial for the treatment of patients with stage 3 and 4 pancreatic cancer. ChemoCentryx, Inc. was founded in 1996 and is headquartered in Mountain View, California.Read More Beat the Market (BTM) Rank™ 4.6 Analyst's Opinion Consensus RatingChemoCentryx has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $69.78, ChemoCentryx has a potential upside of 26.3% from its current price of $55.24.Amount of Analyst CoverageChemoCentryx has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.7 Community Rank Outperform VotesChemoCentryx has received 310 “outperform” votes. (Add your “outperform” vote.)Underperform VotesChemoCentryx has received 273 “underperform” votes. (Add your “underperform” vote.)Community SentimentChemoCentryx has received 53.17% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about ChemoCentryx and other stocks. Vote “Outperform” if you believe CCXI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CCXI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldChemoCentryx does not currently pay a dividend.Dividend GrowthChemoCentryx does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ChemoCentryx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $82,725,155.00 in company stock.Percentage Held by InsidersOnly 9.30% of the stock of ChemoCentryx is held by insiders.Percentage Held by Institutions70.37% of the stock of ChemoCentryx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ChemoCentryx are expected to decrease in the coming year, from ($1.39) to ($1.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ChemoCentryx is -50.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ChemoCentryx is -50.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChemoCentryx has a P/B Ratio of 48.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.6Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.65 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:CCXI Previous Symbol CUSIP16383L10 CIK1340652 Webwww.chemocentryx.com Phone650-210-2900Debt Debt-to-Equity Ratio0.40 Current Ratio3.22 Quick Ratio3.22Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$36.13 million Price / Sales94.56 Cash FlowN/A Price / Cash FlowN/A Book Value$1.14 per share Price / Book48.46Profitability EPS (Most Recent Fiscal Year)($0.98) Net Income$-55,490,000.00 Net Margins-192.93% Return on Equity-100.55% Return on Assets-30.75%Miscellaneous Employees82 Outstanding Shares61,850,000Market Cap$3.42 billion Next Earnings Date8/10/2020 (Confirmed) OptionableOptionable $55.24 +0.75 (+1.38 %) (As of 08/7/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CCXI News and Ratings via Email Sign-up to receive the latest news and ratings for CCXI and its competitors with MarketBeat's FREE daily newsletter. ChemoCentryx (NASDAQ:CCXI) Frequently Asked Questions How has ChemoCentryx's stock been impacted by COVID-19 (Coronavirus)? ChemoCentryx's stock was trading at $41.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CCXI stock has increased by 33.0% and is now trading at $55.24. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of ChemoCentryx? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ChemoCentryx. When is ChemoCentryx's next earnings date? ChemoCentryx is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for ChemoCentryx. How can I listen to ChemoCentryx's earnings call? ChemoCentryx will be holding an earnings conference call on Monday, August 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available. How were ChemoCentryx's earnings last quarter? ChemoCentryx Inc (NASDAQ:CCXI) released its earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by $0.05. The biopharmaceutical company had revenue of $6.01 million for the quarter, compared to analyst estimates of $8.90 million. ChemoCentryx had a negative net margin of 192.93% and a negative return on equity of 100.55%. View ChemoCentryx's earnings history. What price target have analysts set for CCXI? 9 brokerages have issued 1-year price objectives for ChemoCentryx's stock. Their forecasts range from $54.00 to $102.00. On average, they expect ChemoCentryx's share price to reach $69.78 in the next year. This suggests a possible upside of 26.3% from the stock's current price. View analysts' price targets for ChemoCentryx. Has ChemoCentryx been receiving favorable news coverage? News coverage about CCXI stock has trended very negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. ChemoCentryx earned a news impact score of -3.4 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about ChemoCentryx. Are investors shorting ChemoCentryx? ChemoCentryx saw a decline in short interest in the month of July. As of July 31st, there was short interest totaling 4,960,000 shares, a decline of 6.1% from the July 15th total of 5,280,000 shares. Based on an average daily trading volume, of 718,700 shares, the days-to-cover ratio is currently 6.9 days. Currently, 9.9% of the shares of the company are short sold. View ChemoCentryx's Short Interest. Who are some of ChemoCentryx's key competitors? Some companies that are related to ChemoCentryx include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Novavax (NVAX). View all competitors. What other stocks do shareholders of ChemoCentryx own? Based on aggregate information from My MarketBeat watchlists, some companies that other ChemoCentryx investors own include Exelixis (EXEL), Energy Transfer LP Unit (ET), Dynavax Technologies (DVAX), Amicus Therapeutics (FOLD), Gilead Sciences (GILD), Arrowhead Pharmaceuticals (ARWR), Advanced Micro Devices (AMD), Opko Health (OPK), NVIDIA (NVDA) and Inovio Pharmaceuticals (INO). Who are ChemoCentryx's key executives? ChemoCentryx's management team includes the following people: Dr. Thomas J. Schall Ph.D., Founder, Pres, CEO & Chairman (Age 61, Pay $968.76k)Ms. Susan M. Kanaya, Exec. VP, Chief Financial & Admin. Officer and Sec. (Age 57, Pay $696.65k)Dr. Markus J. Cappel, Sr. VP, Chief Bus. Officer & Treasurer (Age 59, Pay $563.8k)Ms. Kari E. Leetch, Sr. VP of HRDr. Catherine Lee Kelleher, Sr. VP of Clinical Devel. What is ChemoCentryx's stock symbol? ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI." Who are ChemoCentryx's major shareholders? ChemoCentryx's stock is owned by a number of retail and institutional investors. Top institutional investors include Emerald Advisers LLC (0.65%), Emerald Mutual Fund Advisers Trust (0.59%), International Biotechnology Trust PLC (0.31%), UBS Group AG (0.23%), Swiss National Bank (0.15%) and Alps Advisors Inc. (0.14%). Company insiders that own ChemoCentryx stock include (International) Ltd Vifor, Geoffrey M Parker, James L Tyree, Markus J Cappel, Plc Glaxosmithkline, Pui San Kwan, Rajinder Singh, Susan M Kanaya and Thomas J Schall. View institutional ownership trends for ChemoCentryx. Which institutional investors are selling ChemoCentryx stock? CCXI stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Alps Advisors Inc., WINTON GROUP Ltd, Chartwell Investment Partners LLC, Virtus ETF Advisers LLC, SG Americas Securities LLC, Trexquant Investment LP, and Genesee Capital Advisors LLC. Company insiders that have sold ChemoCentryx company stock in the last year include (International) Ltd Vifor, Geoffrey M Parker, James L Tyree, Markus J Cappel, Pui San Kwan, Susan M Kanaya, and Thomas J Schall. View insider buying and selling activity for ChemoCentryx. Which institutional investors are buying ChemoCentryx stock? CCXI stock was bought by a variety of institutional investors in the last quarter, including Mutual of America Capital Management LLC, Emerald Mutual Fund Advisers Trust, First Trust Advisors LP, Emerald Advisers LLC, Raymond James Financial Services Advisors Inc., Swiss National Bank, Russell Investments Group Ltd., and Rafferty Asset Management LLC. View insider buying and selling activity for ChemoCentryx. How do I buy shares of ChemoCentryx? Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is ChemoCentryx's stock price today? One share of CCXI stock can currently be purchased for approximately $55.24. How big of a company is ChemoCentryx? ChemoCentryx has a market capitalization of $3.42 billion and generates $36.13 million in revenue each year. The biopharmaceutical company earns $-55,490,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. ChemoCentryx employs 82 workers across the globe. What is ChemoCentryx's official website? The official website for ChemoCentryx is www.chemocentryx.com. How can I contact ChemoCentryx? ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900 or via email at [email protected] This page was last updated on 8/9/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
